GEHC Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

5.60B

+5.29%

1.399

-3.53%

5.01B

+4.8%

0.997

-1.28%

5.23B

+4.39%

1.159

+9.34%

Estimates Revision

The market is revising Upward the revenue expectations for GE HealthCare Technologies Inc. (GEHC) for FY2025, with the revenue forecasts being adjusted by 0.34% over the past three months. During the same period, the stock price has changed by 9.00%.

Revenue Estimates for FY2025

Revise Upward

+0.34%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.98%

In Past 3 Month

Stock Price

Go Up

+9.00%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast GEHC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GEHC is 88.18 USD with a low forecast of 80.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

5 Hold

0 Sell

Moderate Buy

Current: 84.450

Low

80.00

Averages

88.18

High

95.00

Current: 84.450

Low

80.00

Averages

88.18

High

95.00

Jefferies

Jay Saccaro

maintain

$95 -> $105

2025-12-11

New

Reason

Jefferies

Jay Saccaro

Price Target

$95 -> $105

2025-12-11

New

maintain

Reason

Jefferies raised the firm's price target on GE HealthCare to $105 from $95 and keeps a Buy rating on the shares after having hosted a call with CFO Jay Saccaro and other executives. The firm, which was "encouraged" by GE HealthCare's Q3 performance and leading indicators, sees stable to improving fundamentals and "a strong catalyst path" with consensus appearing to model very little contribution from Flyrcado or Vizamyl/Cerianna, the analyst tells investors.

Citi

Neutral

maintain

$83 -> $88

2025-12-11

New

Reason

Citi

Price Target

$83 -> $88

2025-12-11

New

maintain

Neutral

Reason

Citi raised the firm's price target on GE HealthCare to $88 from $83 and keeps a Neutral rating on the shares. The firm adjusted ratings and targets in the medical technology sector as part of its 2026 outlook. The group is "bouncing off its lows," and there is further upside potential in 2026, the analyst tells investors in a research note. Citi believes the S&P Equipment and Supplies index "remains undervalued and underappreciated." The firm expects a rebound next year due to company catalysts and sector rotation.

Wells Fargo

Larry Biegelsen

Overweight

maintain

$89 -> $87

2025-10-30

Reason

Wells Fargo

Larry Biegelsen

Price Target

$89 -> $87

2025-10-30

maintain

Overweight

Reason

Wells Fargo analyst Larry Biegelsen lowered the firm's price target on GE HealthCare to $87 from $89 and keeps an Overweight rating on the shares. The firm notes the company delivered a beat on the top line and EPS of $1.07 was ahead of both consensus and Wells Fargo's estimates. EBIT margins were down 150bps year-over-year, but above the firm's estimates. GE HealthCa raised the lower end of 2025 EPS guidance, but Flyrcado to be less than $30M in 2025 sales.

Morgan Stanley

Patrick Wood

Equal Weight

maintain

$74 -> $80

2025-10-29

Reason

Morgan Stanley

Patrick Wood

Price Target

$74 -> $80

2025-10-29

maintain

Equal Weight

Reason

Morgan Stanley analyst Patrick Wood raised the firm's price target on GE HealthCare to $80 from $74 and keeps an Equal Weight rating on the shares. The firm said it updated its model for Q3 earnings, which were slightly above expectations. Demand is looking solid for GE HealthCare, with solid order backlog and peer results, and the firm's hospital CapEx survey suggests a healthy environment, the analyst tells investors in a research note. The analyst added that it equally believes mid-term margin targets are sensible and sees upside risk long-term from photon counting.

BTIG

Buy

downgrade

$89 -> $87

2025-10-29

Reason

BTIG

Price Target

$89 -> $87

2025-10-29

downgrade

Buy

Reason

BTIG lowered the firm's price target on GE HealthCare to $87 from $89 and keeps a Buy rating on the shares following Q3 results. The firm, which thinks focus shifts to FY26, views the Street forecast for about 4% organic revenue growth with adjusted EPS of $4.93 as "achievable" given GE HealthCare's performance history, the analyst tells investors.

BTIG

Buy

maintain

$82 -> $87

2025-07-14

Reason

BTIG

Price Target

$82 -> $87

2025-07-14

maintain

Buy

Reason

BTIG raised the firm's price target on GE HealthCare to $87 from $82 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.

Valuation Metrics

The current forward P/E ratio for GE Healthcare Technologies Inc (GEHC.O) is 17.56, compared to its 5-year average forward P/E of 18.20. For a more detailed relative valuation and DCF analysis to assess GE Healthcare Technologies Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

18.20

Current PE

17.56

Overvalued PE

20.01

Undervalued PE

16.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

11.44

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

13.01

Undervalued EV/EBITDA

9.87

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.74

Current PS

0.00

Overvalued PS

2.00

Undervalued PS

1.48

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 129.92% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GEHC News & Events

Events Timeline

No data

News

8.5

12-12Barron's

This GE Spinoff Outperforms the S&P 500, Nvidia, and Bitcoin: Here's the Strategy Behind It.

8.5

12-12Barron's

GE Divided into Three in 2021: The Role of AI in Transforming GE Vernova into a High-Performing Stock.

3.5

12-11NASDAQ.COM

Tempus AI's Strategic Initiative to Broaden Its Focus Beyond Cancer Care

People Also Watch

Frequently Asked Questions

What is GE Healthcare Technologies Inc (GEHC) stock price today?

The current price of GEHC is 84.45 USD — it has increased 0.58 % in the last trading day.

What is GE Healthcare Technologies Inc (GEHC)'s business?

GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.

What is the price predicton of GEHC Stock?

What is GE Healthcare Technologies Inc (GEHC)'s revenue for the last quarter?

GE Healthcare Technologies Inc revenue for the last quarter amounts to 5.14B USD, increased 5.76 % YoY.

What is GE Healthcare Technologies Inc (GEHC)'s earnings per share (EPS) for the last quarter?

GE Healthcare Technologies Inc. EPS for the last quarter amounts to 0.98 USD, decreased -3.92 % YoY.

What changes have occurred in the market's expectations for GE Healthcare Technologies Inc (GEHC)'s fundamentals?

How many employees does GE Healthcare Technologies Inc (GEHC). have?

GE Healthcare Technologies Inc (GEHC) has 53000 emplpoyees as of December 16 2025.

What is GE Healthcare Technologies Inc (GEHC) market cap?

Today GEHC has the market capitalization of 38.47B USD.